Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
- Author:
Adie VILJOEN
1
;
Stephen C. BAIN
Author Information
- Publication Type:Review Article
- From:Endocrinology and Metabolism 2023;38(1):25-33
- CountryRepublic of Korea
- Language:English
- Abstract: The therapeutic benefits of the incretin hormone, glucagon-like peptide 1 (GLP1), for people with type 2 diabetes and/or obesity, are now firmly established. The evidence-base arising from head-to-head comparative effectiveness studies in people with type 2 diabetes, as well as the recommendations by professional guidelines suggest that GLP1 receptor agonists should replace more traditional treatment options such as sulfonylureas and dipeptidyl-peptidase 4 (DPP4) inhibitors. Furthermore, their benefits in reducing cardiovascular events in people with type 2 diabetes beyond improvements in glycaemic control has led to numerous clinical trials seeking to translate this benefit beyond type 2 diabetes. Following early trial results their therapeutic benefit is currently being tested in other conditions including fatty liver disease, kidney disease, and Alzheimer’s disease.
